Skip to main content
OpenTrials
Completed

NCT Number: NCT01552174

Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice

The purpose of this study is to determine the incidence and characteristics of eyelid inflammatory disorders during general ophthalmological consultations and to demonstrate association between palpebral pathologies and ocular surface pathologies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Palpebral Pathologies Eye Diseases Eyelid Diseases Meibomian Gland Dysfunction Ocular Surface Disease

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Consultation office, Heidelberg, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Outpatients of either sex, aged at least 18 years, seen in general ophthalmological consultation
  • Patients informed of the objectives of the survey and agreeing to participate.
  • Patient attending to the ophthalmological consultation for any reasons: regular check-up of chronic disease, acute symptoms, or for surgery preparation or follow up.

Treatment and study plan

Primary outcomes

  1. Incidence of eyelid disorders in general ophthalmological practice

    Time frame: Day 1

    • Systematic description of the eyelid, the ocular surface and the dermatological aspect of the face
    • Occurrence of Meibomian Gland Dysfunction(MGD).

Secondary outcomes

  1. Association between palpebral pathologies and ocular surface pathologies

    Time frame: Day 1

    To describe association between palpebral pathologies and ocular surface pathologies

  2. Impact of eyelid disorder on patient's daily life

    Time frame: Day 1

    Consequences on vision, on daily life activities/work, on leisure, on contact lens wearing, on emotions, on sleeping,

  3. Current recommended strategy to treat eyelids disorders

    Time frame: Day 1

    Description of recommended strategy

Sponsors and collaborators

Lead sponsor

Laboratoires Thea

Industry

Collaborators

  • Axial Biotech, Inc
  • Iris Pharma

Registry information

Acronym: MEIBUM

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Mar 13, 2012
Registry last updated
Sep 1, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.